Stephen Hoge - 23 Feb 2026 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
President
Signature
/s/ James Dillon, as Attorney-in-Fact
Issuer symbol
MRNA
Transactions as of
23 Feb 2026
Net transactions value
-$4,750,667
Form type
4
Filing time
25 Feb 2026, 16:49:00 UTC
Previous filing
13 Feb 2026
Next filing
03 Mar 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Hoge Stephen President C/O MODERNA, INC., 325 BINNEY STREET, CAMBRIDGE /s/ James Dillon, as Attorney-in-Fact 25 Feb 2026 0001760669

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Options Exercise $2,138,653 +111,679 +7.7% $19.15 1,569,106 23 Feb 2026 Direct F1
transaction MRNA Common Stock Options Exercise $925,520 +48,330 +3.1% $19.15 1,617,436 23 Feb 2026 Direct F1
transaction MRNA Common Stock Sale $7,814,840 -160,009 -9.9% $48.84 1,457,427 23 Feb 2026 Direct F1
holding MRNA Common Stock 4,116 23 Feb 2026 By Valhalla, LLC
holding MRNA Common Stock 151,933 23 Feb 2026 By Trust F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -111,679 -50% $0.000000 111,678 23 Feb 2026 Common Stock 111,679 $19.15 Direct F1, F3
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -48,330 -50% $0.000000 48,330 23 Feb 2026 Common Stock 48,330 $19.15 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2025.
F2 These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
F3 This option is fully vested and exercisable.